GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Chemed Corp (NYSE:CHE) » Definitions » Altman Z-Score

Chemed (Chemed) Altman Z-Score

: 13.93 (As of Today)
View and export this data going back to 1982. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 13.93 is strong.

Chemed has a Altman Z-Score of 13.93, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Chemed's Altman Z-Score or its related term are showing as below:

CHE' s Altman Z-Score Range Over the Past 10 Years
Min: 6.22   Med: 11.22   Max: 13.93
Current: 13.93

During the past 13 years, Chemed's highest Altman Z-Score was 13.93. The lowest was 6.22. And the median was 11.22.


Chemed Altman Z-Score Historical Data

The historical data trend for Chemed's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.48 13.60 11.03 11.44 13.66

Chemed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.44 13.23 13.14 12.92 13.66

Competitive Comparison

For the Medical Care Facilities subindustry, Chemed's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemed Altman Z-Score Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Chemed's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Chemed's Altman Z-Score falls into.



Chemed Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Chemed's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1132+1.4*1.4669+3.3*0.2119+0.6*16.1425+1.0*1.3575
=13.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $1,668 Mil.
Total Current Assets was $501 Mil.
Total Current Liabilities was $312 Mil.
Retained Earnings was $2,447 Mil.
Pre-Tax Income was 115.593 + 93.265 + 70.344 + 71.165 = $350 Mil.
Interest Expense was -0.342 + -0.444 + -0.771 + -1.551 = $-3 Mil.
Revenue was 585.912 + 564.532 + 553.816 + 560.157 = $2,264 Mil.
Market Cap (Today) was $9,043 Mil.
Total Liabilities was $560 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(500.843 - 312.05)/1668.095
=0.1132

X2=Retained Earnings/Total Assets
=2446.925/1668.095
=1.4669

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(350.367 - -3.108)/1668.095
=0.2119

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=9043.337/560.219
=16.1425

X5=Revenue/Total Assets
=2264.417/1668.095
=1.3575

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Chemed has a Altman Z-Score of 13.93 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Chemed  (NYSE:CHE) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Chemed Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Chemed's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemed (Chemed) Business Description

Traded in Other Exchanges
Address
255 East Fifth Street, Suite 2600, Cincinnati, OH, USA, 45202-4726
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative-care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
Executives
Kevin J Mcnamara director, officer: president & ceo 2500 CHEMED CENTER, 255 EAST FIFTH ST, CINCINNATI OH 45202
Spencer S Lee officer: vice president 2500 CHEMED CENTER, 255 EAST FIFTH ST, CINCINNATI OH 45202
David Patrick Williams officer: Vice President & CFO
Nicholas Michael Westfall officer: Executive Vice President 8035 PEREGRINE LANE, CINCINNATI OH 45243
Patrick P Grace director 1100 PARK AVE, APT 15C, NEW YORK NY 10128
Eileen P Mccarthy director 3515 78TH STREET, #2, JACKSON HEIGHTS NY 11372
Michael D Witzeman officer: vice president and controller 255 E 5TH STREET, SUITE 2600, CINCINNATI OH 45202
Mount John Meredith Jr. director 2906 MABRY ROAD NE, ATLANTA GA 30319
Donald E Saunders director 306 MIANI TRAIL, OXFORD OH 45056
Christopher J Heaney director 101 S. FORT LAUDERDALE BEACH BLVD., APARTMENT 1602, FORT LAUDERDALE FL 33316
Ron Delyons director 2692 MADISON ROAD, SUITE N1-313, CINCINNATI OH 45208
Naomi C Dallob officer: VP and Chief Legal Officer 255 EAST FIFTH STREET, SUITE 2600, CINCINNATI OH 45202
Thomas C Hutton director, officer: vice president ONE ROCKEFELLER PLAZA, STE 1510, NEW YORK NY 10020
Walsh George J Iii director ONE CHASE MANHATTAN PLAZA, NEW YORK NY 10005
Andrea R Lindell director